---
title: "Sanofi's Sarclisa Moves Toward Broader First-Line Access In Canada"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305694129.md"
description: "Sanofi signed a Letter of Intent with Canada's pCPA to expand public access to Sarclisa for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation. The agreement covers Sarclisa combined with VRd as a first-line treatment, pending final provincial funding agreements. Clinical data from the Phase 3 IMROZ study showed improved progression-free survival compared to VRd alone."
datetime: "2026-11-16T15:15:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305694129.md)
  - [en](https://longbridge.com/en/news/305694129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305694129.md)
generator: "portal-rs"
---

# Sanofi's Sarclisa Moves Toward Broader First-Line Access In Canada

Add  as your preferred news source on Google

 Add Now

Sanofi SA (SNY) signed a Letter of Intent with Canada's pan-Canadian Pharmaceutical Alliance (pCPA) following successful negotiations to expand public access to Sarclisa (isatuximab) for adults with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation. 

The agreement covers Sarclisa combined with bortezomib, lenalidomide and dexamethasone (VRd) as a first-line treatment. Public coverage will depend on final funding agreements with individual provinces and territories. 

In the Phase 3 IMROZ study, 63% of patients receiving Sarclisa plus VRd remained progression-free after approximately five years, compared with 45% receiving VRd alone.

Currently, SNY is trading at $48.79, up 0.84% 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)

## Related News & Research

- [EU Approves Sanofi's VaxRabeo Rabies Vaccine for All Ages](https://longbridge.com/en/news/306067816.md)
- [Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It](https://longbridge.com/en/news/303773793.md)
- [Nurix says Sanofi discontinues autoimmune disease drug program](https://longbridge.com/en/news/304167932.md)
- [Merck Pulls Plug On Acquired Drug after Safety Review](https://longbridge.com/en/news/305995345.md)
- [Is ServiceNow (NOW) Trading At Too High A Premium For Earnings?](https://longbridge.com/en/news/306039339.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**